Early recurrence risk: Aromatase inhibitors versus tamoxifen

Expert Review of Anticancer Therapy

Volumn 10, Issue 8, 2010, Pages 1239-1253

  Bria, Emilio ^a   Carlini, Paolo ^a   Cuppone, Federica ^a   Vaccaro, Vanja ^a   Milella, Michele ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

anastrozole; aromatase inhibitor; distant metastases; early breast cancer; exemestane; letrozole

Indexed keywords

ANASTROZOLE; CHOLESTEROL; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; KI 67 ANTIGEN; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SIZE; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG SAFETY; DRUG SUBSTITUTION; EARLY CANCER; ENDOMETRIUM CANCER; FRACTURE; HOT FLUSH; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MASTECTOMY; MONOTHERAPY; MYALGIA; OSTEOLYSIS; OUTCOME ASSESSMENT; PHARMACOGENOMICS; POSTMENOPAUSE; POSTOPERATIVE CARE; PROTEIN EXPRESSION; RECURRENCE RISK; RECURRENT CANCER; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; STROKE; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; TAMOXIFEN; TIME FACTORS;

EID: 77956253940     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.54     Document Type: Review

References (73)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18, 581-592 (2007).
2. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
3. Demicheli R, Terenziani M, Valagussa P et al. Local recurrences following mastectomy: support for the concept of tumor dormancy. J. Natl Cancer Inst. 86, 45-48 (1994).
4. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol. 14, 2738-2746 (1996).
5. Mansell J, Monypenny IJ, Skene AI et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res. Treat. 117, 91-98 (2009).
6. Elder EE, Kennedy CW, Gluch L et al. Patterns of breast cancer relapse. Eur. J. Surg. Oncol. 32, 922-927 (2006).
7. Lamerato L, Havstad S, Gandhi S, Jones D, Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. J. Clin. Oncol. 23(16S), 62s (2005) (Abstract 738).
8. Lê MG, Arriagada R, Spielmann M, Guinebretiére J-M, Rochard F. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer 94, 2813-2820 (2002).
9. Howell A, Cuzick J, Baum M et al.; ATAC Trialists Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
10. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45-53 (2008).
11. Thürlimann B, Keshaviah A, Coates AS et al.; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005).
12. Coates AS, Keshaviah A, Thürlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25, 486-492 (2007).
13. BIG 1-98 Collaborative Group; Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med. 361, 766-776 (2009).
14. Thürlimann B; BIG 1-98 Collaborative Group. Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer. Update of the BIG 1-98 primary core analysis. Presented at: 11th International St Gallen Oncology Conference: Primary Therapy of Early Breast Cancer. St Gallen, Switzerland, 11-14 March 2009. (Abstract 0161).
15. Coombes RC, Hall E, Gibson LJ et al.; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350, 1081-1092 (2004).
16. Coombes RC, Kilburn LS, Snowdon CF et al. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369, 559-570 (2007).
17. Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol. 23, 5138-5147 (2005).
18. Kaufmann M, Jonat W, Hilfrich J et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J. Clin. Oncol. 25, 2664-2670 (2007).
19. Jakesz R, Jonat W, Gnant M et al.; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366, 455-462 (2005).
20. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol. 16, 1569-1583 (2005).
21. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ; 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann. Oncol. 18, 1133-1144 (2007).
22. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann. Oncol. 20, 1319-1329 (2009).
23. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 23, 619-629 (2005).
24. Kryj M, Maciejewski B, Withers HR, Taylor JM. Incidence and kinetics of distant metastases in patients with operable breast cancer. Neoplasma 44, 3-11 (1997).
25. Lawrence G, Pritchard MG, Kearins O, Casey M. An analysis of breast cancer recurrences for screen detected and symptomatic breast cancers diagnosed in the West Midlands in 1996 and 1997. Breast Cancer Res. Treat. 94(Suppl. 1), S211 (2005) (Abstract 5019).
26. Oh S, Heflin L, Meyerowitz BE, Desmond KA, Rowland JH, Ganz PA. Quality of life of breast cancer survivors after a recurrence: a follow-up study. Breast Cancer Res. Treat. 87, 45-57 (2004).
27. Rugo H. Adjuvant therapies: distant disease-free survival as a predictor of overall survival. Breast 16(Suppl. 1), S47 (2007) (Abstract P120).
28. Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med. 347, 1227-1232 (2002).
29. Jung SY, Han W, Lee JW et al. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann. Surg. Oncol. 16, 1112-1121 (2009).
30. Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J. Natl Cancer Inst. 100, 642-648 (2008).
31. Rutqvist LE, Cedermark B, Glas U et al. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res. Treat. 10, 255-266 (1987).
32. Rutqvist LE, Johansson H; Stockholm Breast Cancer Study Group. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol. 46, 133-145 (2007).
33. 'Nolvadex' Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br. J. Cancer 57, 608-611 (1988).
34. McArthur HL, Olivotto I, Gelmon KA et al. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Res. Treat. 94(Suppl. 1), S124 (2005) (Abstract 3001).
35. Muss HB, Bunn JY, Crocker A et al. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen. Breast J. 13, 337-345 (2007).
36. Baum M, Buzdar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359, 2131-2139 (2002).
37. Baum M, Buzdar A, Cuzick J et al.; ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98, 1802-1810 (2003).
38. Houghton J. Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) - data reported on behalf of the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trialists' group. Ann. Oncol. 17(Suppl. 9), ix94 (2006) (Abstract 243PD).
39. Houghton J; on behalf of the ATAC Trialists' Group. A detailed analysis of the risk factors influencing local and distant breast cancer recurrence during adjuvant endocrine therapy. J. Clin. Oncol. 25(18S), 18s (2007) (Abstract 562).
40. Mauriac L, Keshaviah A, Debled M et al.; BIG 1-98 Collaborative Group; International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann. Oncol. 18, 859-867 (2007).
41. Viale G, Giobbie-Hurder A, Regan MM et al.; Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from BreastInternational Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J. Clin. Oncol. 26, 5569-5575 (2008).
42. Ingle JN, Dowsett M, Cuzick J, Davies C. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. Cancer Res. 69(Suppl.), 66s (2009) (Abstract 12).
43. Jones SE, Seynaeve C, Hasenburg A et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized Phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res. 69(Suppl.), 67s (2009) (Abstract 15).
44. Rea D, Hasenburg A, Seynaeve C, Jones S, Vannetzel J, Paridaens R. Five years of exemestane as initial therapy compared with 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, Phase III trial in postmenopausal women with hormone-sensitive early breast cancer. Cancer Res. 69(24 Suppl.) (2009) (Abstract 11).
45. Gligorov J, Azria D, Pivot X, Penault- Llorca F, Spielmann M, Namer M. Clinical impact of upfront adjuvant AI therapy on the early risk of recurrence. Eur. J. Cancer 5, 209 (2007) (Abstract 2.089).
46. Rugo HS, Dranitsaris G, Kaura S. Application of number needed to treat (NNT) to compare benefit: letrozole or anastrozole for the prevention of early recurrences in postmenopausal women with early breast cancer. Ann. Oncol. 19(Suppl. 8), viii81 (2008) (Abstract 195P).
47. Rugo HS, Dranitsaris G, Kaura S. The number needed to treat to save a life: a comparison between aromatase inhibitors. Breast 18(Suppl. 1), S52 (Abstract 0136) (2009).
48. Bhatnagar AS, Brodie AM, Long BJ, Evans DB, Miller WR. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J. Steroid Biochem. Mol. Biol. 76, 199-202 (2001).
49. Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J. Clin. Oncol. 26, 1671-1676 (2008).
50. Geisler J, Helle H, Ekse D et al. Letrozole is superior to anastrozole suppressing breast cancer tissue and plasma estrogen levels. Clin. Cancer Res. 14, 6330-6445 (2008).
51. Rose C, Vtoraya O, Pluzanska A et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer 39, 2318-2327 (2003).
52. De Boer R Sr, Burris HA, Monnier A et al.; on behalf of the H2H trial steering committee. The Head to Head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. J. Clin. Oncol. 24(18s), 582s (2006) (Abstract 10672).
53. Jakesz R, Gnant M, Greil R et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG trial 8. Breast Cancer Res. Treat. 94(Suppl. 1), S10 (2005) (Abstract 13).
54. Jakesz R, Gnant M, Greil R et al. Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. Cancer Res. 69(Suppl.), 67s (2009) (Abstract 14).
55. Bria E, Ciccarese M, Giannarelli D et al. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients. Cancer Treat. Rev. 32, 325-332 (2006).
56. Jonat W, Gnant M, Boccardo F et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 7, 991-996 (2006).
57. Wang Z, Kyo S, Maida Y et al. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Oncogene 21, 3517-3524 (2002).
58. Gielen SC, Santegoets LA, Hanifi- Moghaddam P, Burger CW, Blok LJ. Signaling by estrogens and tamoxifen in the human endometrium. J. Steroid Biochem. Mol. Biol. 109, 219-223 (2008).
59. Constantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J. Natl Cancer Inst. 89, 776-782 (1997).
60. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. Br. Med. J. 311, 977-980 (1995).
61. Stein O, Stein Y. Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis 178, 217-230 (2005).
62. Kusama M, Kaise H, Nakayama S, Ota D, Misaka T, Aoki T. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations. Breast Cancer Res. Treat. 88, 9-16 (2004).
63. Decensi A, Maisonneuve P, Rotmensz N et al.; Italian Tamoxifen Study Group. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 111, 650-656 (2005).
64. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J. Gen. Intern. Med. 18, 937-947 (2003).
65. Duffy S; on Behalf of the ATAC Trialists' Group. Anastrozole is associated with a lower risk of endometrial abnormalities than tamoxifen: first report of the ATAC trial endometrial sub-protocol at 6 years follow-up. Breast Cancer Res. Treat. 100(Suppl. 1), S190 (2006) (Abstract 4055).
66. Boccardo F, Rubagotti A, Guglielmini P et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann. Oncol. 17(Suppl. 7), vii10-vii14 (2006).
67. Cuzick J, Wale C; on behalf of the ATAC Trialists' Group. A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years treatment. Breast Cancer Res. Treat. 100(Suppl. 1), S24 (2006) (Abstract 104).
68. Houghton J; on behalf of the ATAC Trialists' Group. Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: updated data from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. J. Clin. Oncol. 23(Suppl. 16), 24S (2005) (Abstract 582).
69. Cuzick J, Sestak I, Cella D, Fallowfield L; ATAC Trialists' Group. Treatmentemergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 9, 1143-1148 (2008).
70. Cuzick J. Hot flushes and the risk of recurrence: retrospective, exploratory results from the ATAC trial. Breast Cancer Res. Treat. 106(Suppl. 1), S108 (2007) (Abstract 2069).
71. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst. 97, 1262-1271 (2005).
72. Monnier A, Sakek N, Aladen S. Comparing AI cardiovascular safety data: trial comparators and outcomes. Breast 16(Suppl. 1), S43 (2007).
73. Cuppone F, Bria E, Verma S et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 112, 260-267 (2008).